Publications:

---

[Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells].

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi

Dong, X Y XY; Li, Y L YL; Wu, C Y CY; Shang, B J BJ; Zhang, L L; Cheng, W W; Zhu, Z M ZM

Publication Date: 2021-08-14

Variant appearance in text: CP: F317V

PubMed Link: 34547872

Variant Present in the following documents:

• Main text
• cjh-42-08-660.pdf

View BVdb publication page

---

Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Asian Pacific Journal Of Cancer Prevention : Apjcp

Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N

Publication Date: 2020-12-01

Variant appearance in text: CP: F317V

PubMed Link: 33369447

Variant Present in the following documents:

• Main text
• APJCP-21-3517.pdf

View BVdb publication page

---

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal Of Haematology : Official Journal Of Turkish Society Of Haematology

Haznedaroğlu, İbrahim C. İC; Kuzu, Işınsu I; İlhan, Osman O

Publication Date: 2020-02-20

Variant appearance in text: CP: F317V

PubMed Link: 31612694

Variant Present in the following documents:

• TJH-37-42.pdf

View BVdb publication page

---

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Haematologica

Gambacorti-Passerini, Carlo C; Cortes, Jorge E JE; Lipton, Jeff H JH; Kantarjian, Hagop M HM; Kim, Dong-Wook DW; Schafhausen, Philippe P; Crescenzo, Rocco R; Bardy-Bouxin, Nathalie N; Shapiro, Mark M; Noonan, Kay K; Leip, Eric E; DeAnnuntis, Liza L; Brümmendorf, Tim H TH; Khoury, H Jean HJ

Publication Date: 2018-08

Variant appearance in text: CP: F317V

PubMed Link: 29773593

Variant Present in the following documents:

• 2017.171249.GAMBACORTI-PASSERINI_SUPPL.pdf

View BVdb publication page

---

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Sadovnik, Irina I; Hoelbl-Kovacic, Andrea A; Herrmann, Harald H; Eisenwort, Gregor G; Cerny-Reiterer, Sabine S; Warsch, Wolfgang W; Hoermann, Gregor G; Greiner, Georg G; Blatt, Katharina K; Peter, Barbara B; Stefanzl, Gabriele G; Berger, Daniela D; Bilban, Martin M; Herndlhofer, Susanne S; Sill, Heinz H; Sperr, Wolfgang R WR; Streubel, Berthold B; Mannhalter, Christine C; Holyoake, Tessa L TL; Sexl, Veronika V; Valent, Peter P

Publication Date: 2016-04-15

Variant appearance in text: CP: F317V

PubMed Link: 26607600

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Dasatinib-related chylothorax.

Turkish Journal Of Haematology : Official Journal Of Turkish Society Of Haematology

Huang, Yen Min YM; Wang, Cheng Hsu CH; Huang, Jen Seng JS; Yeh, Kun Yun KY; Lai, Chien Hong CH; Wu, Tsung Han TH; Chang, Pei Hung PH; Chang, Pei Hung PH; Chang, Yueh Shih YS; Lan, Yii Jenq YJ

Publication Date: 2015-03-05

Variant appearance in text: CP: F317V

PubMed Link: 25805678

Variant Present in the following documents:

• TJH-32-68.pdf

View BVdb publication page

---

Therapy of chronic myeloid leukemia: twilight of the imatinib era?

Isrn Oncology

Trela, Ewelina E; Glowacki, Sylwester S; Błasiak, Janusz J

Publication Date: 2014

Variant appearance in text: CP: F317V

PubMed Link: 24634785

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.

Mediterranean Journal Of Hematology And Infectious Diseases

Breccia, Massimo M; Alimena, Giuliana G

Publication Date: 2014-01-02

Variant appearance in text: CP: F317V

PubMed Link: 24455112

Variant Present in the following documents:

• Main text
• mjhid-6-1-e2014003.pdf

View BVdb publication page

---

Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.

Pharmacogenomics And Personalized Medicine

Rassi, Fuad El FE; Khoury, Hanna Jean HJ

Publication Date: 2013-08-05

Variant appearance in text: CP: F317V

PubMed Link: 24019749

Variant Present in the following documents:

• pgpm-6-057.pdf

View BVdb publication page

---

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Blood

Khorashad, Jamshid S JS; Kelley, Todd W TW; Szankasi, Philippe P; Mason, Clinton C CC; Soverini, Simona S; Adrian, Lauren T LT; Eide, Christopher A CA; Zabriskie, Matthew S MS; Lange, Thoralf T; Estrada, Johanna C JC; Pomicter, Anthony D AD; Eiring, Anna M AM; Kraft, Ira L IL; Anderson, David J DJ; Gu, Zhimin Z; Alikian, Mary M; Reid, Alistair G AG; Foroni, Letizia L; Marin, David D; Druker, Brian J BJ; O'Hare, Thomas T; Deininger, Michael W MW

Publication Date: 2013-01-17

Variant appearance in text: CP: F317V

PubMed Link: 23223358

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

Journal Of Blood Medicine

Lima, Lisa M LM; Arellano, Martha M; Holloway, Stacie S; Shepard, Marian M; McMillan, Stephanie S; Khoury, Hanna Jean HJ

Publication Date: 2010

Variant appearance in text: CP: F317V

PubMed Link: 22282699

Variant Present in the following documents:

• Main text
• jbm-1-221.pdf

View BVdb publication page

---

Optimizing combination therapies with existing and future CML drugs.

Plos One

Katouli, Allen A AA; Komarova, Natalia L NL

Publication Date: 2010-08-23

Variant appearance in text: CP: F317V

PubMed Link: 20808800

Variant Present in the following documents:

• pone.0012300.pdf

View BVdb publication page

---

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Clinical Therapeutics

Stein, Brady B; Smith, B Douglas BD

Publication Date: 2010-05

Variant appearance in text: CP: F317V

PubMed Link: 20685492

Variant Present in the following documents:

• Main text

View BVdb publication page

---

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.

Journal Of Hematology & Oncology

Cang, Shundong S; Liu, Delong D

Publication Date: 2008-10-01

Variant appearance in text: CP: F317V

PubMed Link: 18828913

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Therapeutics And Clinical Risk Management

Henkes, Martin M; van der Kuip, Heiko H; Aulitzky, Walter E WE

Publication Date: 2008-02

Variant appearance in text: CP: Phe317Val

PubMed Link: 18728706

Variant Present in the following documents:

• tcrm-0401-163.pdf

View BVdb publication page

---